RT Journal Article
SR Electronic
T1 ISARIC COVID-19 Clinical Data Report issued: 15 December 2021
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.17.20155218
DO 10.1101/2020.07.17.20155218
A1 ,
A1 Baillie, J. Kenneth
A1 Baruch, Joaquin
A1 Beane, Abigail
A1 Blumberg, Lucille
A1 Bozza, Fernando Augusto
A1 Broadley, Tessa
A1 Burrell, Aidan
A1 Carson, Gail
A1 Citarella, Barbara Wanjiru
A1 Dunning, Jake
A1 Elotmani, Loubna
A1 Barrio, Noelia Garcia
A1 Goffard, Jean-Christophe
A1 Goncalves, Bronner
A1 Hall, Matthew
A1 Hashmi, Madiha
A1 Horby, Peter
A1 Jassat, Waasila
A1 Jayakumar, Devachandran
A1 Kartsonaki, Christiana
A1 Vijayaraghavan, Bharath Kumar Tirupakuzhi
A1 Vecham, Pavan Kumar
A1 Laouenan, Cedric
A1 Lissauer, Samantha
A1 Martin-Loeches, Ignacio
A1 Mentre, France
A1 Morton, Ben
A1 Munblit, Daniel
A1 Nekliudov, Nikita A.
A1 Nichol, Alistair
A1 Ong, David S.Y.
A1 Panda, Prasan Kumar
A1 Jimenez, Miguel Pedrera
A1 Petrovic, Michelle
A1 Ramakrishnan, Nagarajan
A1 Ramos, Grazielle Viana
A1 Roger, Claire
A1 Rojek, Amanda
A1 Sandulescu, Oana
A1 Semple, Malcolm G.
A1 Sharma, Pratima
A1 Sigfrid, Louise
A1 Heng, Benedict Sim Lim
A1 Singh, Budha Charan
A1 Somers, Emily
A1 Streinu-Cercel, Anca
A1 Taccone, Fabio S.
A1 Wei, Jia
A1 Wils, Evert-Jan
A1 Wong, Xin Ci
A1 Olliaro, Piero L.
A1 Merson, Laura
YR 2022
UL http://medrxiv.org/content/early/2022/01/05/2020.07.17.20155218.abstract
AB ISARIC (International Severe Acute Respiratory and emerging Infections Consortium) partnerships and outbreak preparedness initiatives enabled the rapid launch of standardised clinical data collection on COVID-19 in Jan 2020. Extensive global uptake of this resource has resulted in a large, standardised collection of comprehensive clinical data from hundreds of sites across dozens of countries. Data are analysed regularly and reported publicly to inform patient care and public health response. This report, our 16th report, is a part of a series. Data have been entered for 706,747 individuals from 1669 partner institutions and networks across 64 countries.The comprehensive analyses detailed in this report includes hospitalised individuals of all ages for whom data collection occurred between 30 January 2020 and up to and including 21 September 2021, AND who have laboratory-confirmed SARS-COV-2 infection or clinically diagnosed COVID-19.For the 614,497 cases who meet eligibility criteria for this report, selected findings include: o median age of 58 years, with an approximately equal (50/50) male:female sex distributiono one third of the cohort are at least 70 years of age, whereas 4% are 0-19 years of ageo the most common symptom combination in this hospitalised cohort is shortness of breath, cough, and history of fever, which has remained constant over timeo the five most common symptoms at admission were shortness of breath, cough, history of fever, fatigue/malaise, and altered consciousness/confusion, which is unchanged from the previous reportso age-associated differences in symptoms are evident, including the frequency of altered consciousness increasing with age, and fever, respiratory and constitutional symptoms being present mostly in those 40 years and aboveo 15% of patients with relevant data available were admitted at some point during their illness into an intensive care unit (ICU), which is slightly lower than previously reported (19%)o antibiotic use remains very high (56%), although it is lower than previously reported (80%), in those for whom relevant data are available (379,319); in ICU/HDU patients with data available (42,841), 91% received antibioticso use of corticosteroids was reported for 24% of patients of all types for whom data were available (593,701); in ICU/HDU patients with data available (42,791), 67% received corticosteroidso outcomes are known for 556,928 patients and the overall estimated case fatality ratio (CFR) is 25.3% (95%CI 25.2-25.4), rising to 38.7% (95%CI 38.3-39) for patients who were admitted to ICU/HDU, demonstrating worse outcomes in those with the most severe disease We thank all the data contributors for their ongoing support. This report is the next in a series retrievable at https://doi.org/10.1101/2020.07.17.20155218To access previous versions of ISARIC COVID-19 Clinical Data Report please use the link below: https://isaric.org/research/covid-19-clinical-research-resources/evidence-reports/ERRATUM for https://doi.org/10.1101/2020.07.17.20155218Due to a fault in processing of the data for the ISARIC Clinical Data Report issued 14 July 2021, the following results in that version of the report had errors: - Time periods: Length of hospital stay and symptom onset to admission- Patients who received oxygen therapy ever, including: the number of patients who were administered corticosteroids while on oxygen therapy but not IMV; the number of patients who were administered corticosteroids and did not receive oxygen therapy, proportion of patients who received oxygen therapy, and proportion of patients who received oxygen while in ICU These figures have been corrected in this version of the report.NB: the methods for assessing the proportion of patients that meet the 4 most common COVID-19 case definitions have been updated in this version of the report. Only patients with no missing data for the symptoms included in the corresponding definition are included in this analysis.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://isaric.net/ccp/ https://isaric4c.net/ Funding StatementThis work was made possible by the UK Foreign; Commonwealth and Development Office; Wellcome [215091/Z/18/Z] [205228/Z/16/Z] [220757/Z/20/Z]; Bill & Melinda Gates Foundation [OPP1209135]; the philanthropic support of the donors to the University of Oxford COVID19 Research Response Fund; the Prince Charles Hospital Foundation; Australia; Australian Department of Health grant (3273191); Gender Equity Strategic Fund at University of Queensland; Artificial Intelligence for Pandemics (A14PAN) at University of Queensland; the Australian Research Council Centre of Excellence for Engineered Quantum Systems (EQUS CE170100009); UK Medical Research Council Clinical Research Training Fellowship MR/V001671/1; CIHR Coronavirus Rapid Research Funding Opportunity OV2170359 and the coordination in Canada by Sunnybrook Research Institute; endorsement of the Irish Critical Care Clinical Trials Group; coordination in Ireland by the Irish Critical Care Clinical Trials Network at University College Dublin and funding by the Health Research Board of Ireland [CTN 2014 12]; the Rapid European COVID19 Emergency Response research (RECOVER) [H2020 project 101003589] and European Clinical Research Alliance on Infectious Diseases (ECRAID) [965313]; the COVID clinical management team; AIIMS; Rishikesh; India; Cambridge NIHR Biomedical Research Centre; the dedication and hard work of the Groote Schuur Hospital Covid ICU Team; support by the Groote Schuur nursing and University of Cape Town registrar bodies coordinated by the Division of Critical Care at the University of Cape Town; the Liverpool School of Tropical Medicine and the University of Oxford; the dedication and hard work of the Norwegian SARS CoV2 study team; the Research Council of Norway grant no 312780; and a philanthropic donation from Vivaldi Invest A/S owned by Jon Stephenson von Tetzchner; Imperial NIHR Biomedical Research Centre; Innovative Medicines Initiative Joint Undertaking under Grant Agreement No. 115523 COMBACTE; resources of which are composed of financial contribution from the European Union Seventh Framework Programme (FP7/2007 2013) and EFPIA companies; in kind contribution; is sponsored by INSERM and funded by the REACTing (REsearch & ACtion emergING infectious diseases) consortium and by a grant of the French Ministry of Health (PHRC n20 0424); Stiftungsfonds zur Forderung der Bekampfung der Tuberkulose und anderer Lungenkrankheiten of the City of Vienna; Project Number: APCOV22BGM; Italian Ministry of Health Fondi Ricerca corrente L1P6 to IRCCS Ospedale Sacro Cuore Don Calabria; grants from Instituto de Salud Carlos III; Ministerio de Ciencia; Spain; Brazil; National Council for Scientific and Technological Development Scholarship number 303953/2018 7; the Firland Foundation; Shoreline; Washington; USA; and preparedness work conducted by the Short Period Incidence Study of Severe Acute Respiratory Infection. This work uses Data / Material provided by patients and collected by the NHS as part of their care and support #DataSavesLives. The Data / Material used for this research were obtained from ISARIC4C. The COVID19 Clinical Information Network (CO CIN) data was collated by ISARIC4C Investigators. Data and Material provision was supported by grants from: the National Institute for Health Research (NIHR; award CO CIN 01); the Medical Research Council (MRC; grant MC PC 19059); and by the NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE); (award 200907); NIHR HPRU in Respiratory Infections at Imperial College London with PHE (award 200927); Liverpool Experimental Cancer Medicine Centre (grant C18616/A25153); NIHR Biomedical Research Centre at Imperial College London (award IS BRC 1215 20013); and NIHR Clinical Research Network providing infrastructure support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee approval for this work was given by the World Health Organisation Ethics Review Committee (RPC571 and RPC572 on 25 April 2013). Institutional approval was additionally obtained by participating sites including the South Central Oxford C Research Ethics Committee in England (Ref 13/SC/0149) and the Scotland A Research Ethics Committee (Ref 20/SS/0028) for the United Kingdom and the Human Research Ethics Committee (Medical) at the University of the Witwatersrand in South Africa as part of a national surveillance programme (M160667) collectively representing the majority of the data. Other institutional and national approvals are in place as per local requirements.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe welcome applications for access to data on the COVID-19 Data Sharing Platform via the Data Access Committee (www.iddo.org/covid-19). https://www.iddo.org/covid-19